Sign in
4

Changes in Ownership

Prelude Therapeutics Inc Filed Acc 0001824632-26-000002

Options or other derivatives

  • Chief Scientific Officer acquired 230,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Scherle Peggy Chief Scientific Officer 2026-02-04 Grant or award · Employee Stock Option (right to buy) +230,000 230,000 D
Loading xslF345X05/primarydocument.xml…